Kristiansen K, Hagen S, Kollevold T, Torvik A, Holme I, Nesbakken R, Hatlevoll R, Lindgren M, Brun A, Lindgren S, Notter G, Andersen A P, Elgen K
Cancer. 1981 Feb 15;47(4):649-52. doi: 10.1002/1097-0142(19810215)47:4<649::aid-cncr2820470405>3.0.co;2-w.
In a controlled, prospective, randomized investigation, started in 1974, 118 patients with supratentorial astrocytoma Grade III--IV were divided into three groups. Groups 1 and 2 received 45 Gy postoperatively to the whole supratentorial brain. Bleomycin in 15-mg doses and a total dose of 180 mg or placebo was given intravenously three times a week, one hour prior to radiotherapy, during weeks 1, 2, 4 and 5. Group 3 received conventional care but no radiotherapy or chemotherapy. Median survival rates of patients were 10.8 months in Groups 1 and 2, and 5.2 months in Groups 3, a statistically significant difference. With regard to performance, the patients in Group 3 deteriorated faster than patients in Groups 1 and 2. Bleomycin had no positive or negative influence on survival.
在一项始于1974年的对照、前瞻性、随机调查中，118例幕上III - IV级星形细胞瘤患者被分为三组。第1组和第2组术后接受全幕上脑45 Gy的放疗。在第1、2、4和5周，每周三次在放疗前一小时静脉注射15毫克剂量的博来霉素，总剂量为180毫克或安慰剂。第3组接受常规护理，但不进行放疗或化疗。第1组和第2组患者的中位生存期为10.8个月，第3组为5.2个月，差异有统计学意义。在身体状况方面，第3组患者比第1组和第2组患者恶化得更快。博来霉素对生存期没有正面或负面影响。
